Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective

Open access
Dawkins, Hugh J.S., Draghia‐Akli, Ruxandra, Lasko, Paul, Lau, Lilian P.L., Jonker, Anneliene H., Cutillo, Christine M., Rath, Ana, Boycott, Kym M., Baynam, Gareth, Lochmüller, Hanns, Kaufmann, Petra, Le Cam, Yann, Hivert, Virginie, Austin, Christopher P., International Rare Diseases Research Consortium (IRDiRC) · 2018 · Clinical and Translational Science

Abstract

Rare diseases by definition are conditions that affect small numbers of people. The prevalence threshold that designates a disease as rare varies in different countries. Generally, diseases with prevalence fewer than 5 in 10,000 people are considered rare.1 Many rare diseases affect far fewer people worldwide, with some having a single identified case and others with cases numbering from tens to low hundreds of people.2 However, collectively, they are common. There are ∼6,000–8,000 rare diseases, with 250–280 new diseases described annually, affecting an estimated 6–8% of the human population.3-6 The rarity of these diseases individually creates significant challenges for affected patients, their families, and for clinicians attempting to achieve a confirmed diagnosis and implement best care.7, 8 Obtaining a correct diagnosis is frequently a difficult and lengthy process, as physicians and caregivers often lack appropriate expertise in a disease that they rarely encounter.4 Effective therapeutics are lacking for the large majority of these diseases, and when they exist, they are often very expensive because of scientific and manufacturing challenges, and small potential markets for such products; this creates barriers to access that are frequently difficult to resolve.3 Rare diseases are chronic and often severely disabling, thus treating these patients places a substantial burden on healthcare budgets. For example, one recent study from Western Australia concluded that in 2010 the state population affected by a limited cohort of only 467 rare diseases represented 2% of the population but 10.5% of in-patient hospital costs.9 Therefore, improved diagnostics and targeted therapeutics that keep these patients healthier and reduce their time in medical facilities would be highly beneficial. Many rare diseases resemble common ones and involve the same genetic pathways, but are generally more aggressive or severe in their presentation. Improved understanding of these diseases may therefore be relevant to improving or developing diagnostics and therapeutics for their more common counterparts. Most rare diseases are genetic in their etiology, thus research addressing them systematically begins with efforts to identify genetic variants that are causative for particular diseases.1, 5 Such research has been under way for decades and has been successful, with many links between genetic mutations and diseases identified. However, by the mid-2000s it became increasingly apparent that several factors were limiting success and needed to be addressed systematically on an international scale. Linking a genetic variant with a particular disease requires finding two or, preferably, more unrelated individuals who have a genetic variant in common, as well as exhibiting similar phenotypic characteristics. Identifying such matches can be facilitated by data sharing, but due to at times competitive academic framework and limitations in the consent obtained from research participants, data sharing among research groups working on the same disease was often limited or nonexistent. An additional problem was the lack of a standardized vocabulary to describe phenotypes, further complicating the identification of patients with similar symptoms.10 At the same time, the advent of next-generation genomic techniques, which dramatically increased throughput and lowered cost, provided the opportunity to drastically accelerate the discovery of gene–disease connections.11 However, with this promise came the additional technical challenges of storing, analyzing, sending, and comparing large sets of data. The introduction of regulatory and economic incentives (e.g., market exclusivity, fee waivers, protocol assistance) was also successful in attracting the biopharmaceutical industry, which was previously reluctant to invest in rare disease therapeutic development with little or limited return on investment.5 Prior to the introduction of the Orphan Drug Act in the US in 1983, only 10 orphan drugs were approved in a decade, compared with 247 drugs for over 200 rare diseases in the course of the 25 years postlegislation.12 In Europe, following the adoption of the European Commission (EC) Regulation 141/2000, 63 orphan medicinal products received marketing authorization by 2010, a decade after implementation.13 While a large increase in the number of orphan designations was seen on both sides of the Atlantic, the average combined number of orphan-designated products approved was about 15 per year and they addressed only a handful of rare diseases. By 2010, ∼400 orphan medicinal products were available for less than 300 rare diseases. Additionally, observations by the US Food and Drug Administration (FDA) of a slowdown instead of the expected acceleration in innovative medical therapies reaching patients were also reported in the mid-2000s.14 Attrition rate aside, therapy development for rare diseases faces a number of specific challenges, including sm

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cts.12501

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 178

Metadata

Authors
Dawkins, H. J. S., Draghia‐Akli, R., Lasko, P., Lau, L. P. L., Jonker, A. H., Cutillo, C. M., Rath, A., Boycott, K. M., Baynam, G., Lochmüller, H., Kaufmann, P., Le Cam, Y., Hivert, V., Austin, C. P., & International Rare Diseases Research Consortium (IRDiRC)
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2017-10-23
Volume
11
Issue
1
Pages
11-20
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W2743245152
Cited by
178
References
2
FWCI
9.98
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.